EyePoint Pharmaceuticals, Inc.·4

Feb 11, 4:48 PM ET

ANDO GORAN 4

4 · EyePoint Pharmaceuticals, Inc. · Filed Feb 11, 2022

Insider Transaction Report

Form 4
Period: 2022-02-09
ANDO GORAN
Director
Transactions
  • Exercise/Conversion

    Common Stock

    2022-02-09+2,7504,900 total
  • Award

    Restricted Stock Units

    2022-02-09+3,2503,250 total
    Exercise: $0.00Common Stock (3,250 underlying)
  • Exercise/Conversion

    Restricted Stock Units

    2022-02-092,7500 total
    Exercise: $0.00Common Stock (2,750 underlying)
  • Award

    Stock Option (Right to Buy)

    2022-02-09+12,00012,000 total
    Exercise: $10.13From: 2023-02-09Exp: 2032-02-09Common Stock (12,000 underlying)
Footnotes (2)
  • [F1]Will fully vest on the one-year anniversary of the grant date.
  • [F2]Fully vested on the one-year anniversary of the grant date.

Documents

1 file
  • 4
    primarydocument.xmlPrimary

    PRIMARY DOCUMENT